# Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

> **NCT00468767** · PHASE3 · COMPLETED · sponsor: **Advanz Pharma** · enrollment: 356 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Vernakalant Injection 20 mg/mL

## Key facts

- **NCT ID:** NCT00468767
- **Lead sponsor:** Advanz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2008-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00468767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00468767, "Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00468767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*